Percutaneous renal cryoablation

Local control at mean 26 months of followup

Thomas D. Atwell, Matthew R Callstrom, Michael A. Farrell, Grant D. Schmit, David A Woodrum, Bradley C. Leibovich, George K. Chow, David E. Patterson, Michael L. Blute, J. William Charboneau

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Purpose: We retrospectively determined the efficacy of percutaneous renal cryoablation based on a mean followup of more than 2 years. Materials and Methods: Institutional review board approval was obtained for this Health Insurance Portability and Accountability Act compliant retrospective study. Informed consent was waived. From March 2003 through March 2007, 91 patients with 93 tumors underwent 92 percutaneous cryoablation procedures. Technical success was defined as extension of the ice ball beyond the tumor margin and post-ablation images showing no contrast enhancement in the area encompassing the original tumor within 3 months of the procedure. Local tumor progression was defined as new enhancement in the ablated tumor or an increase in ablated tumor size beyond 3 months after the procedure. Complications were defined using the National Cancer Institute Common Terminology Criteria for Adverse Events v3.0. Results: Mean followup was 26 months (range 5 to 61, SD ±13) and mean tumor size was 3.4 cm (range 1.5 to 7.3, SD ±1.2). Major complications occurred in 6 of 91 patients (7%) or after 8 of 92 (9%) procedures. Technically successful ablation was performed in the treatment of 89 of the 93 (96%) tumors or 87 of the 91 patients (96%). Of the 83 tumors with followup longer than 3 months only a single case (1%) of local tumor progression occurred. Overall local control was achieved in 86 of 91 (95%) patients or 88 of 93 (95%) tumors. Conclusions: Midterm followup of percutaneous renal cryoablation shows durability of this treatment method with a low incidence of tumor recurrence beyond 3 months.

Original languageEnglish (US)
Pages (from-to)1291-1295
Number of pages5
JournalJournal of Urology
Volume184
Issue number4
DOIs
StatePublished - Oct 2010

Fingerprint

Cryosurgery
Kidney
Neoplasms
Health Insurance Portability and Accountability Act
National Cancer Institute (U.S.)
Research Ethics Committees
Ice
Informed Consent
Terminology
Retrospective Studies

Keywords

  • carcinoma
  • cryosurgery
  • renal cell

ASJC Scopus subject areas

  • Urology
  • Medicine(all)

Cite this

Atwell, T. D., Callstrom, M. R., Farrell, M. A., Schmit, G. D., Woodrum, D. A., Leibovich, B. C., ... Charboneau, J. W. (2010). Percutaneous renal cryoablation: Local control at mean 26 months of followup. Journal of Urology, 184(4), 1291-1295. https://doi.org/10.1016/j.juro.2010.06.003

Percutaneous renal cryoablation : Local control at mean 26 months of followup. / Atwell, Thomas D.; Callstrom, Matthew R; Farrell, Michael A.; Schmit, Grant D.; Woodrum, David A; Leibovich, Bradley C.; Chow, George K.; Patterson, David E.; Blute, Michael L.; Charboneau, J. William.

In: Journal of Urology, Vol. 184, No. 4, 10.2010, p. 1291-1295.

Research output: Contribution to journalArticle

Atwell, TD, Callstrom, MR, Farrell, MA, Schmit, GD, Woodrum, DA, Leibovich, BC, Chow, GK, Patterson, DE, Blute, ML & Charboneau, JW 2010, 'Percutaneous renal cryoablation: Local control at mean 26 months of followup', Journal of Urology, vol. 184, no. 4, pp. 1291-1295. https://doi.org/10.1016/j.juro.2010.06.003
Atwell, Thomas D. ; Callstrom, Matthew R ; Farrell, Michael A. ; Schmit, Grant D. ; Woodrum, David A ; Leibovich, Bradley C. ; Chow, George K. ; Patterson, David E. ; Blute, Michael L. ; Charboneau, J. William. / Percutaneous renal cryoablation : Local control at mean 26 months of followup. In: Journal of Urology. 2010 ; Vol. 184, No. 4. pp. 1291-1295.
@article{2b0c8ae7978748f4b8e8d891be04cc5a,
title = "Percutaneous renal cryoablation: Local control at mean 26 months of followup",
abstract = "Purpose: We retrospectively determined the efficacy of percutaneous renal cryoablation based on a mean followup of more than 2 years. Materials and Methods: Institutional review board approval was obtained for this Health Insurance Portability and Accountability Act compliant retrospective study. Informed consent was waived. From March 2003 through March 2007, 91 patients with 93 tumors underwent 92 percutaneous cryoablation procedures. Technical success was defined as extension of the ice ball beyond the tumor margin and post-ablation images showing no contrast enhancement in the area encompassing the original tumor within 3 months of the procedure. Local tumor progression was defined as new enhancement in the ablated tumor or an increase in ablated tumor size beyond 3 months after the procedure. Complications were defined using the National Cancer Institute Common Terminology Criteria for Adverse Events v3.0. Results: Mean followup was 26 months (range 5 to 61, SD ±13) and mean tumor size was 3.4 cm (range 1.5 to 7.3, SD ±1.2). Major complications occurred in 6 of 91 patients (7{\%}) or after 8 of 92 (9{\%}) procedures. Technically successful ablation was performed in the treatment of 89 of the 93 (96{\%}) tumors or 87 of the 91 patients (96{\%}). Of the 83 tumors with followup longer than 3 months only a single case (1{\%}) of local tumor progression occurred. Overall local control was achieved in 86 of 91 (95{\%}) patients or 88 of 93 (95{\%}) tumors. Conclusions: Midterm followup of percutaneous renal cryoablation shows durability of this treatment method with a low incidence of tumor recurrence beyond 3 months.",
keywords = "carcinoma, cryosurgery, renal cell",
author = "Atwell, {Thomas D.} and Callstrom, {Matthew R} and Farrell, {Michael A.} and Schmit, {Grant D.} and Woodrum, {David A} and Leibovich, {Bradley C.} and Chow, {George K.} and Patterson, {David E.} and Blute, {Michael L.} and Charboneau, {J. William}",
year = "2010",
month = "10",
doi = "10.1016/j.juro.2010.06.003",
language = "English (US)",
volume = "184",
pages = "1291--1295",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Percutaneous renal cryoablation

T2 - Local control at mean 26 months of followup

AU - Atwell, Thomas D.

AU - Callstrom, Matthew R

AU - Farrell, Michael A.

AU - Schmit, Grant D.

AU - Woodrum, David A

AU - Leibovich, Bradley C.

AU - Chow, George K.

AU - Patterson, David E.

AU - Blute, Michael L.

AU - Charboneau, J. William

PY - 2010/10

Y1 - 2010/10

N2 - Purpose: We retrospectively determined the efficacy of percutaneous renal cryoablation based on a mean followup of more than 2 years. Materials and Methods: Institutional review board approval was obtained for this Health Insurance Portability and Accountability Act compliant retrospective study. Informed consent was waived. From March 2003 through March 2007, 91 patients with 93 tumors underwent 92 percutaneous cryoablation procedures. Technical success was defined as extension of the ice ball beyond the tumor margin and post-ablation images showing no contrast enhancement in the area encompassing the original tumor within 3 months of the procedure. Local tumor progression was defined as new enhancement in the ablated tumor or an increase in ablated tumor size beyond 3 months after the procedure. Complications were defined using the National Cancer Institute Common Terminology Criteria for Adverse Events v3.0. Results: Mean followup was 26 months (range 5 to 61, SD ±13) and mean tumor size was 3.4 cm (range 1.5 to 7.3, SD ±1.2). Major complications occurred in 6 of 91 patients (7%) or after 8 of 92 (9%) procedures. Technically successful ablation was performed in the treatment of 89 of the 93 (96%) tumors or 87 of the 91 patients (96%). Of the 83 tumors with followup longer than 3 months only a single case (1%) of local tumor progression occurred. Overall local control was achieved in 86 of 91 (95%) patients or 88 of 93 (95%) tumors. Conclusions: Midterm followup of percutaneous renal cryoablation shows durability of this treatment method with a low incidence of tumor recurrence beyond 3 months.

AB - Purpose: We retrospectively determined the efficacy of percutaneous renal cryoablation based on a mean followup of more than 2 years. Materials and Methods: Institutional review board approval was obtained for this Health Insurance Portability and Accountability Act compliant retrospective study. Informed consent was waived. From March 2003 through March 2007, 91 patients with 93 tumors underwent 92 percutaneous cryoablation procedures. Technical success was defined as extension of the ice ball beyond the tumor margin and post-ablation images showing no contrast enhancement in the area encompassing the original tumor within 3 months of the procedure. Local tumor progression was defined as new enhancement in the ablated tumor or an increase in ablated tumor size beyond 3 months after the procedure. Complications were defined using the National Cancer Institute Common Terminology Criteria for Adverse Events v3.0. Results: Mean followup was 26 months (range 5 to 61, SD ±13) and mean tumor size was 3.4 cm (range 1.5 to 7.3, SD ±1.2). Major complications occurred in 6 of 91 patients (7%) or after 8 of 92 (9%) procedures. Technically successful ablation was performed in the treatment of 89 of the 93 (96%) tumors or 87 of the 91 patients (96%). Of the 83 tumors with followup longer than 3 months only a single case (1%) of local tumor progression occurred. Overall local control was achieved in 86 of 91 (95%) patients or 88 of 93 (95%) tumors. Conclusions: Midterm followup of percutaneous renal cryoablation shows durability of this treatment method with a low incidence of tumor recurrence beyond 3 months.

KW - carcinoma

KW - cryosurgery

KW - renal cell

UR - http://www.scopus.com/inward/record.url?scp=79953140726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953140726&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2010.06.003

DO - 10.1016/j.juro.2010.06.003

M3 - Article

VL - 184

SP - 1291

EP - 1295

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 4

ER -